Xilio Therapeutics, Inc. (XLO)
NASDAQ: XLO · Real-Time Price · USD
7.92
-0.26 (-3.18%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Xilio Therapeutics Ratios and Metrics
Market cap in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
| Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| Market Capitalization | 46 | 34 | 42 | 15 | 74 | 437 | |
| Market Cap Growth | 33.72% | -19.94% | 177.26% | -79.46% | -83.14% | - | |
| Enterprise Value | -85 | -63 | -11 | -30 | -45 | 581 | |
| Last Close Price | 7.92 | 8.96 | 13.37 | 7.70 | 37.66 | 224.00 | |
| PS Ratio | 1.05 | 0.77 | 6.62 | - | - | - | |
| PB Ratio | 1.02 | 0.95 | 2.38 | 0.41 | 0.70 | 2.36 | |
| P/TBV Ratio | 1.30 | 0.95 | 2.38 | 0.41 | 0.70 | 2.36 | |
| Debt / Equity Ratio | 0.20 | 0.20 | 0.46 | 0.34 | 0.19 | 0.11 | |
| Net Debt / Equity Ratio | -3.70 | -3.70 | -2.68 | -0.87 | -0.95 | -0.96 | |
| Net Debt / EBITDA Ratio | 3.23 | 3.23 | 0.81 | 0.42 | 1.15 | 2.41 | |
| Net Debt / FCF Ratio | 23.70 | 23.70 | 2.56 | 0.47 | 1.29 | 2.17 | |
| Asset Turnover | 0.39 | 0.39 | 0.10 | - | - | - | |
| Quick Ratio | 2.53 | 2.53 | 2.03 | 2.80 | 5.70 | 15.50 | |
| Current Ratio | 2.58 | 2.58 | 2.21 | 3.02 | 5.90 | 15.85 | |
| Return on Equity (ROE) | -132.53% | -132.53% | -214.02% | -107.25% | -60.62% | -84.16% | |
| Return on Assets (ROA) | -23.24% | -23.24% | -56.48% | -49.44% | -31.20% | -36.88% | |
| Return on Capital Employed (ROCE) | -42.70% | -42.70% | -136.10% | -176.00% | -75.50% | -36.60% | |
| Earnings Yield | -76.50% | -104.24% | -138.74% | -504.62% | -119.66% | -17.33% | |
| FCF Yield | -12.03% | -16.39% | -43.86% | -456.42% | -105.24% | -18.72% | |
| Buyback Yield / Dilution | -18.53% | -18.53% | -94.61% | -0.38% | -388.59% | -970.35% | |
Source: S&P Capital IQ. Standard template.
Financial Sources.